Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

US Supreme Court Mulls Patenting of Human Genes

By BiotechDaily International staff writers
Posted on 10 Dec 2012
The US Supreme Court (Washington DC, USA) will soon decide whether companies can patent human genes, which could reshape medical research and the fight against various diseases.

The case in question involves patents filed by Myriad Genetics (Salt Lake City, UT, USA) on two breast cancer (BRCA) predisposition genes for which the company has developed a specific test that identifies mutations on these genes that are associated with much greater risks of breast and ovarian cancer. The American Civil Liberties Union (New York, NY, USA) challenged those patents, arguing that genes could not be patented, and in March 2010, a US district judge agreed and invalidated the patents, stating that “DNA's existence in an isolated form does not alter the fundamental quality of DNA as it exists in the body or the information it encodes.”

However, the US Federal Appeals Court reversed that decision in 2011, claiming Myriad's genes can be patented because the isolated DNA has a markedly different chemical structure from DNA within the body. Later on, the US Supreme Court invalidated that decision and sent the case back to the lower courts for rehearing. The decision came after the Supreme Court unanimously threw out patents on a Prometheus Laboratories (San Diego, CA, USA) test that assists doctors to set drug doses for autoimmune diseases like Crohn's disease, saying, “The laws of nature are unpatentable.”

However, in August 2012, the US Federal Circuit Court once again upheld Myriad's patents, leading to the current review. It is expected that in this round before the Supreme Court, the justices' decision will likely resolve an ongoing battle between scientists who believe that genes carrying the secrets of life should not be exploited for commercial gain, and companies that argue that a patent is a reward for years of expensive research that moves science forward.

“It's wrong to think that something as naturally occurring as DNA can be patented by a single company that limits scientific research and the free exchange of ideas,” said Chris Hansen, staff attorney with the ACLU Speech, Privacy and Technology Project.

Myriad’s company's lawyers responded, according to court papers, that without being able to patent and profit from their work, the company would not be able to fund the type of medical breakthroughs doctors depend on. The company also said that deciding now that genes cannot be patented would throw into chaos current research and profits structures for drug-makers, and medical research companies, who have been granted more than 40,000 DNA-related patents from the US Patent and Trademark Office in almost 30 years.

Related Links:

US Supreme Court
Myriad Genetics
Prometheus Laboratories



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.